JP2020510043A5 - - Google Patents

Download PDF

Info

Publication number
JP2020510043A5
JP2020510043A5 JP2019549420A JP2019549420A JP2020510043A5 JP 2020510043 A5 JP2020510043 A5 JP 2020510043A5 JP 2019549420 A JP2019549420 A JP 2019549420A JP 2019549420 A JP2019549420 A JP 2019549420A JP 2020510043 A5 JP2020510043 A5 JP 2020510043A5
Authority
JP
Japan
Prior art keywords
administered
receptor antagonist
pharmaceutically acceptable
acceptable salt
manufacture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019549420A
Other languages
English (en)
Japanese (ja)
Other versions
JP7580918B2 (ja
JP2020510043A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2018/056372 external-priority patent/WO2018167139A1/en
Publication of JP2020510043A publication Critical patent/JP2020510043A/ja
Publication of JP2020510043A5 publication Critical patent/JP2020510043A5/ja
Priority to JP2023008155A priority Critical patent/JP2023052576A/ja
Application granted granted Critical
Publication of JP7580918B2 publication Critical patent/JP7580918B2/ja
Priority to JP2024230902A priority patent/JP2025060907A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019549420A 2017-03-15 2018-03-14 P2y12受容体アンタゴニストの皮下投与 Active JP7580918B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023008155A JP2023052576A (ja) 2017-03-15 2023-01-23 P2y12受容体アンタゴニストの皮下投与
JP2024230902A JP2025060907A (ja) 2017-03-15 2024-12-26 P2y12受容体アンタゴニストの皮下投与

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP2017056175 2017-03-15
EPPCT/EP2017/056175 2017-03-15
PCT/EP2018/056372 WO2018167139A1 (en) 2017-03-15 2018-03-14 Subcutaneous administration of a p2y12 receptor antagonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023008155A Division JP2023052576A (ja) 2017-03-15 2023-01-23 P2y12受容体アンタゴニストの皮下投与

Publications (3)

Publication Number Publication Date
JP2020510043A JP2020510043A (ja) 2020-04-02
JP2020510043A5 true JP2020510043A5 (enExample) 2021-04-22
JP7580918B2 JP7580918B2 (ja) 2024-11-12

Family

ID=61899166

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019549420A Active JP7580918B2 (ja) 2017-03-15 2018-03-14 P2y12受容体アンタゴニストの皮下投与
JP2023008155A Pending JP2023052576A (ja) 2017-03-15 2023-01-23 P2y12受容体アンタゴニストの皮下投与
JP2024230902A Pending JP2025060907A (ja) 2017-03-15 2024-12-26 P2y12受容体アンタゴニストの皮下投与

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023008155A Pending JP2023052576A (ja) 2017-03-15 2023-01-23 P2y12受容体アンタゴニストの皮下投与
JP2024230902A Pending JP2025060907A (ja) 2017-03-15 2024-12-26 P2y12受容体アンタゴニストの皮下投与

Country Status (18)

Country Link
US (1) US11179390B2 (enExample)
EP (1) EP3595666A1 (enExample)
JP (3) JP7580918B2 (enExample)
KR (1) KR102510832B1 (enExample)
CN (1) CN110381947A (enExample)
AU (1) AU2018234056B2 (enExample)
BR (1) BR112019014567A2 (enExample)
CL (1) CL2019002318A1 (enExample)
EA (1) EA201992123A1 (enExample)
IL (1) IL269286B2 (enExample)
MA (1) MA49887A (enExample)
MX (1) MX393334B (enExample)
MY (1) MY205605A (enExample)
PH (1) PH12019502111A1 (enExample)
SG (1) SG11201908128YA (enExample)
TW (1) TWI765002B (enExample)
UA (1) UA125531C2 (enExample)
WO (1) WO2018167139A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3515924T3 (da) 2016-09-22 2022-03-21 Idorsia Pharmaceuticals Ltd Krystallinske former
SG11201908128YA (en) * 2017-03-15 2019-10-30 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a p2y12 receptor antagonist
RS67649B1 (sr) 2020-07-15 2026-02-27 Viatris Asia Pacific Pte Ltd Vodena farmaceutska kompozicija koja sadrži antagonistu p2y12 receptora
IL309948A (en) 2021-07-13 2024-03-01 Idorsia Pharmaceuticals Ltd A process for the synthesis of 4-((R)-2-{[6-((S)-3-methoxy-pyrrolidin-1-yl)-2-phenyl-pyrimidin-4-carbonyl]-amino}-3-phosphono- Propionyl)-piperazine-1-carboxylic acid butyl ester
WO2023174810A1 (en) 2022-03-14 2023-09-21 Idorsia Pharmaceuticals Ltd A process for the synthesis of ( r)-2-(( tert-butoxycarbonyl)amino)-3-(diethoxyphosphoryl)propanoic acid or of phosphonate derivatives thereof

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3870035A (en) 1970-07-17 1975-03-11 Survival Technology Method and apparatus for self-administering pre-hospital phase treatment of coronary prone individuals in the early minutes or hours after the onset of heart attack symptoms
US4004577A (en) 1972-12-04 1977-01-25 Survival Technology, Inc. Method of treating heart attack patients prior to the establishment of qualified direct contact personal care
JPS5373586A (en) 1976-12-09 1978-06-30 Mitsubishi Chem Ind Ltd New penicillin derivatives
US4795433A (en) 1985-05-20 1989-01-03 Survival Technology, Inc. Automatic injector for emergency treatment
US4658830A (en) 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
US5078680A (en) 1984-08-08 1992-01-07 Survival Technology, Inc. Automatic injector for emergency treatment
GR861289B (en) 1985-05-20 1986-09-16 Survival Technology Injection method and apparatus with electrical blood absorbing stimulation
CA2020437A1 (en) 1989-07-05 1991-01-06 Yoshihide Fuse Cinnamamide derivative
ES2248084T3 (es) 1999-06-14 2006-03-16 Eli Lilly And Company Inhibidores de serinproteasa.
US6861424B2 (en) 2001-06-06 2005-03-01 Schering Aktiengesellschaft Platelet adenosine diphosphate receptor antagonists
EA200500899A1 (ru) 2002-12-11 2006-02-24 Шеринг Акциенгезельшафт Антагонисты аденозиндифосфатного рецептора тромбоцитов
US7253153B2 (en) 2003-04-09 2007-08-07 Wyeth Derivatives of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and methods of use thereof
AU2003249865A1 (en) 2003-06-24 2005-01-21 Actelion Pharmaceuticals Ltd Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors
TW200640877A (en) 2005-04-28 2006-12-01 Actelion Pharmaceuticals Ltd Pyrimidine derivatives
TWI382976B (zh) 2005-10-21 2013-01-21 Actelion Pharmaceuticals Ltd 作為抗瘧疾劑之新穎哌
CL2007002920A1 (es) 2006-10-13 2008-06-06 Actelion Pharmaceuticals Ltd Compuestos derivados de 2-aminocarbonilpiridina; composicion farmaceutica; y uso para el tratamiento de trastornos vasculares oclusivos.
AR063518A1 (es) 2006-10-25 2009-01-28 Actelion Pharmaceuticals Ltd Derivados 2-fenil-6-aminocarbonil-pirimidina; composicion farmaceutica; y su uso para tratar y/o prevenir enfermedades vasculares perifericas viscerales, hepaticas y renales, enfermedades cardiovasculares y enfermedades cerebrovasculares asociados con la agregacion de plaquetas, incluyendo trombosis
JP4785881B2 (ja) 2007-02-27 2011-10-05 大塚製薬株式会社 医薬
WO2008128647A1 (en) 2007-04-23 2008-10-30 Sanofi-Aventis Quinoline-carboxamide derivatives as p2y12 antagonists
EP2079464A2 (en) 2007-05-02 2009-07-22 Portola Pharmaceuticals, Inc. Intravenous and oral dosing of a direct-acting and reversible p2y12 inhibitor
JP4729133B2 (ja) 2007-11-29 2011-07-20 アクテリオン ファーマシューティカルズ リミテッド ホスホン酸誘導体及びp2y12受容体拮抗剤としてのそれらの使用
EP2238127B1 (en) 2007-12-26 2012-08-15 Sanofi Pyrazole-carboxamide derivatives as p2y12 antagonists
WO2009080226A2 (en) 2007-12-26 2009-07-02 Sanofis-Aventis Heterocyclic pyrazole-carboxamides as p2y12 antagonists
AR071653A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2-fenil-4-ciclopropil-pirimidina
AR071652A1 (es) 2008-04-11 2010-07-07 Actelion Pharmaceuticals Ltd Derivados 2- fenil-piridina substituidos
CA2756542C (en) 2009-04-08 2017-08-22 Actelion Pharmaceuticals Ltd 6-(3-aza-bicyclo[3.1.0]hex-3-yl)-2-phenyl-pyrimidines
CA2756654C (en) 2009-04-22 2017-08-22 Actelion Pharmaceuticals Ltd Thiazole derivatives and their use as p2y12 receptor antagonists
WO2011137459A1 (en) 2010-04-30 2011-11-03 Portola Pharmaceuticals, Inc. Dosage forms of elinogrel and methods of injectable administration thereof
EP2585161A1 (en) 2010-06-23 2013-05-01 Stefan Kralev Medical device for self-administration of patients with acute coronary events
DK3515924T3 (da) 2016-09-22 2022-03-21 Idorsia Pharmaceuticals Ltd Krystallinske former
SG11201908128YA (en) * 2017-03-15 2019-10-30 Idorsia Pharmaceuticals Ltd Subcutaneous administration of a p2y12 receptor antagonist

Similar Documents

Publication Publication Date Title
JP2020510043A5 (enExample)
JP2023002662A5 (enExample)
JP6353577B2 (ja) 組み合わせ組成物
JP2011173928A5 (enExample)
JP2009102342A5 (enExample)
JP2018513188A5 (enExample)
JP2010526101A5 (enExample)
FI3577124T3 (fi) Nukleotidihemisulfaattisuola hepatiitti C -viruksen hoitoon
HRP20221100T1 (hr) Stabilna parenteralna formulacija nimopidina
JP2014516942A5 (enExample)
JP2018197248A (ja) 低減された投与容量を必要とする患者におけるベンダムスチン応答性症状の治療方法
ES2704229T3 (es) Agonistas selectivos del receptor AT2 para su uso en el tratamiento de la caquexia
JP2019517542A5 (enExample)
ES2971959T3 (es) Terlipresina para el tratamiento de la ascitis debida a cirrosis hepática administrada como una infusión continua
EP3528828B1 (en) Terlipressin composition for use in treating ascites
JP2017533211A5 (enExample)
KR20120089623A (ko) 정맥내 투여용 이부프로펜을 이용한 환자의 치료
JP2012526099A5 (enExample)
WO2010110428A1 (ja) 掻痒の予防及び/または治療剤
TWI631944B (zh) 氯硝柳胺及其衍生物的用途
WO2019242688A1 (zh) 3-羟基氨基苯甲酸与索拉非尼联合用药治疗肿瘤
JP2008526816A5 (enExample)
AR062894A1 (es) Formulaciones para administracion terapeutica de hormona de estimulacion del tiroides (ths)
JP2016503406A5 (enExample)
JP2016510738A5 (enExample)